via bizjournals.com
Shire CEO Angus Russell said Wednesday the UK-based specialty pharmaceutical company is now evaluating whether potential drugs can get reimbursed at an acceptable rate by insurers as early as Phase 1 of clinical development, and urged other companies to follow suit.
Speaking at the 2011 BioPharm America conference in Boston, Russell said that the industry landscape has changed more radically in the past five years than in the preceding 25 years, and that survival in the new world requires “market driven R&D, not just clever science for its own sake.”
Russell said he's concerned that he "doesn't see a real sense of urgency to wake up to what's going on" in the industry when it comes to pricing and reimbursement.
No comments:
Post a Comment